Crinetics Pharmaceuticals, Inc. CRNX
We take great care to ensure that the data presented and summarized in this overview for Crinetics Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CRNX
View all-
Vanguard Group Inc Valley Forge, PA9.09MShares$306 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$210 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$207 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$182 Million0.03% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA4.29MShares$144 Million10.24% of portfolio
-
Farallon Capital Management LLC San Francisco, CA4.08MShares$137 Million1.11% of portfolio
-
State Street Corp Boston, MA2.99MShares$101 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X02.8MShares$94.1 Million0.08% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.79MShares$93.8 Million0.34% of portfolio
-
Jennison Associates LLC2.12MShares$71.3 Million0.05% of portfolio
Latest Institutional Activity in CRNX
Top Purchases
Top Sells
About CRNX
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Insider Transactions at CRNX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 02
2025
|
Richard Scott Struthers President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
81,270
+16.53%
|
$81,270
$1.91 P/Share
|
|
Mar 19
2025
|
Richard Scott Struthers President & CEO |
SELL
Open market or private sale
|
Direct |
17,338
-2.51%
|
$589,492
$34.5 P/Share
|
|
Mar 19
2025
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,770
-2.53%
|
$196,180
$34.5 P/Share
|
|
Mar 19
2025
|
Jeff E. Knight Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
7,162
-3.8%
|
$243,508
$34.5 P/Share
|
|
Mar 19
2025
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
2,515
-1.69%
|
$85,510
$34.5 P/Share
|
|
Mar 10
2025
|
Tobin Schilke Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,000
+50.0%
|
-
|
|
Feb 20
2025
|
Stephen F. Betz Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,000
+27.33%
|
-
|
|
Feb 20
2025
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,000
+36.52%
|
-
|
|
Feb 20
2025
|
Jeff E. Knight Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,000
+31.24%
|
-
|
|
Feb 20
2025
|
Richard Scott Struthers President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
89,000
+20.44%
|
-
|
|
Feb 03
2025
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
5,000
-13.61%
|
$195,000
$39.07 P/Share
|
|
Feb 03
2025
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+11.98%
|
$80,000
$16.89 P/Share
|
|
Jan 07
2025
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+7.3%
|
$47,500
$19.64 P/Share
|
|
Jan 03
2025
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
15,000
-33.9%
|
$780,000
$52.09 P/Share
|
|
Jan 03
2025
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+25.32%
|
$240,000
$16.89 P/Share
|
|
Dec 16
2024
|
Stephen F. Betz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,331
+3.16%
|
$2,331
$1.91 P/Share
|
|
Dec 02
2024
|
Richard Scott Struthers President & CEO |
SELL
Open market or private sale
|
Indirect |
10,000
-9.09%
|
$570,000
$57.57 P/Share
|
|
Nov 22
2024
|
Jeff E. Knight Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
501
-0.96%
|
$28,056
$56.52 P/Share
|
|
Oct 03
2024
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
14,375
-33.52%
|
$776,250
$54.63 P/Share
|
|
Oct 03
2024
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,375
+25.11%
|
$230,000
$16.89 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 294K shares |
|---|---|
| Exercise of conversion of derivative security | 409K shares |
| Open market or private sale | 393K shares |
|---|